3 / 5 Stars
4 4 5 5 2
Zacks Investment Research
1 (Strong Buy)
Standard & Poor's
3 / 5 Stars
#9 in Health
U.S. News evaluated 34 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
The fund has returned 34.84 percent over the past year, 22.77 percent over the past three years, 23.37 percent over the past five years, and 11.55 percent over the past decade.
|Trailing Returns||Updated 01.31.2014|
|Year to date||1.7%|
|3 Years (Annualized)||22.8%|
|5 Years (Annualized)||23.4%|
|10 Years (Annualized)||11.5%|
The investment seeks capital appreciation. The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
Fees are Below Average compared to funds in the same category.
Fidelity Select Pharmaceuticals Portfolio has an expense ratio of 0.84 percent.
Risk is Below Average compared to funds in the same category according to Morningstar.